Department of Breast Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, PR China.
J Surg Res. 2012 Dec;178(2):751-7. doi: 10.1016/j.jss.2012.05.030. Epub 2012 May 29.
This prospective cohort study aimed to compare the efficacy of cavity margins (CMs) and lumpectomy margins (LMs) for pathological assessment in breast-conserving surgery.
We assessed the CMs and LMs of 163 breast cancer patients during breast-conserving surgery. We compared and analyzed the positivity rates of CM and LM.
The positivity rate of CM at the case level and individual margin level was 30.7% and 8.0%, respectively. The positivity rate of LM was 12.3%, 33.1%, and 45.4% at the case level and 1.8%, 6.2%, and 9.1% at the individual margin level, when we used the National Surgical Adjuvant Breast and Bowel Project criteria (ink-free), 1 mm-free criteria and 2 mm-free criteria, respectively. The positivity rate of LM with 1 mm-free criteria was similar to that of CM. Delivery of neoadjuvant chemotherapy increased the positivity rate of CM (50.0% versus 25.2%; P < 0.01) but not LM (41.6% versus 30.7%; P > 0.05) at the case level, whereas the positivity rate of CM and LM both increased after neoadjuvant chemotherapy at the margin level (CMs: 15.5% versus 5.6%, P < 0.001; and LMs: 10.7% versus 4.9%, P < 0.001). In univariate and multivariate analysis, delivery of neoadjuvant chemotherapy, higher node-positive stage, and presence of ductal carcinoma in situ component were correlated with positive CM, whereas positive human epidermal growth factor receptor 2 status and higher node-positive stage were associated with positive LM.
Ink-free criteria may be insufficient for LM assessment in breast-conserving surgery, and at least 1 mm width LM is suggested. After the delivery of neoadjuvant chemotherapy, CM assessment should be routinely performed in addition to LM assessment.
本前瞻性队列研究旨在比较保乳手术中腔镜边缘(CMs)和肿瘤切缘(LMs)的病理评估效果。
我们评估了 163 例保乳手术患者的 CMs 和 LMs。我们比较和分析了 CM 和 LM 的阳性率。
CM 在病例水平和个体边缘水平的阳性率分别为 30.7%和 8.0%。LM 的阳性率在病例水平分别为 12.3%、33.1%和 45.4%,在个体边缘水平分别为 1.8%、6.2%和 9.1%,分别采用国家外科辅助乳腺和肠道项目(无墨迹)、1mm 无墨迹和 2mm 无墨迹标准。LM 采用 1mm 无墨迹标准的阳性率与 CM 相似。新辅助化疗的应用增加了 CM 的阳性率(50.0%比 25.2%;P < 0.01),但不增加 LM 的阳性率(41.6%比 30.7%;P > 0.05),但在边缘水平,CM 和 LM 的阳性率均增加(CMs:15.5%比 5.6%,P < 0.001;LMs:10.7%比 4.9%,P < 0.001)。单因素和多因素分析显示,新辅助化疗的应用、较高的淋巴结阳性分期和导管原位癌成分的存在与 CM 阳性相关,而人表皮生长因子受体 2 阳性状态和较高的淋巴结阳性分期与 LM 阳性相关。
无墨迹标准可能不足以评估保乳手术中的 LM,建议至少保留 1mm 宽度的 LM。新辅助化疗后,除了评估 LM 外,还应常规进行 CM 评估。